A novel CSP C-terminal epitope targeted by an antibody with protective activity against Plasmodium falciparum

Potent and durable vaccine responses will be required for control of malaria caused by Plasmodium falciparum (Pf). RTS,S/AS01 is the first, and to date, the only vaccine that has demonstrated significant reduction of clinical and severe malaria in endemic cohorts in Phase 3 trials. Although the vacc...

Descripción completa

Detalles Bibliográficos
Autores principales: Beutler, Nathan, Pholcharee, Tossapol, Oyen, David, Flores-Garcia, Yevel, MacGill, Randall S., Garcia, Elijah, Calla, Jaeson, Parren, Mara, Yang, Linlin, Volkmuth, Wayne, Locke, Emily, Regules, Jason A., Dutta, Sheetij, Emerling, Daniel, Early, Angela M., Neafsey, Daniel E., Winzeler, Elizabeth A., King, C. Richter, Zavala, Fidel, Burton, Dennis R., Wilson, Ian A., Rogers, Thomas F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989322/
https://www.ncbi.nlm.nih.gov/pubmed/35344575
http://dx.doi.org/10.1371/journal.ppat.1010409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989322/
https://www.ncbi.nlm.nih.gov/pubmed/35344575
http://dx.doi.org/10.1371/journal.ppat.1010409

Ejemplares similares